Homestead Advisers Corp reduced its position in shares of Centene Co. (NYSE:CNC – Free Report) by 3.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 779,736 shares of the company’s stock after selling 28,600 shares during the quarter. Homestead Advisers Corp owned 0.15% of Centene worth $47,236,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Osborne Partners Capital Management LLC lifted its stake in Centene by 5.0% in the 4th quarter. Osborne Partners Capital Management LLC now owns 221,156 shares of the company’s stock valued at $13,398,000 after purchasing an additional 10,515 shares during the last quarter. Perpetual Ltd boosted its stake in shares of Centene by 68.4% during the 4th quarter. Perpetual Ltd now owns 36,126 shares of the company’s stock worth $2,189,000 after acquiring an additional 14,671 shares during the period. Polianta Ltd raised its stake in Centene by 41.7% in the 4th quarter. Polianta Ltd now owns 22,100 shares of the company’s stock valued at $1,338,000 after acquiring an additional 6,500 shares during the period. KBC Group NV lifted its holdings in Centene by 27.3% during the 4th quarter. KBC Group NV now owns 1,602,533 shares of the company’s stock valued at $97,082,000 after purchasing an additional 343,559 shares during the last quarter. Finally, Washington Capital Management Inc. boosted its position in Centene by 40.9% during the fourth quarter. Washington Capital Management Inc. now owns 19,130 shares of the company’s stock worth $1,159,000 after purchasing an additional 5,550 shares during the period. Institutional investors and hedge funds own 93.63% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts recently commented on CNC shares. Stephens reduced their target price on shares of Centene from $75.00 to $73.00 and set an “equal weight” rating for the company in a report on Friday, December 13th. Barclays increased their target price on Centene from $91.00 to $93.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. UBS Group upgraded Centene from a “neutral” rating to a “buy” rating and boosted their price target for the company from $79.00 to $80.00 in a research note on Friday, December 13th. Robert W. Baird lifted their target price on Centene from $66.00 to $71.00 in a report on Tuesday, February 4th. Finally, Truist Financial decreased their price target on shares of Centene from $89.00 to $84.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $79.92.
Centene Stock Performance
Centene stock opened at $60.58 on Thursday. The stock has a market cap of $30.05 billion, a PE ratio of 9.71, a P/E/G ratio of 0.80 and a beta of 0.40. The company has a quick ratio of 1.10, a current ratio of 1.11 and a debt-to-equity ratio of 0.70. Centene Co. has a 12-month low of $55.03 and a 12-month high of $80.59. The business’s 50-day moving average price is $60.04 and its two-hundred day moving average price is $62.88.
Centene (NYSE:CNC – Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.49 by $0.31. The business had revenue of $40.81 billion during the quarter, compared to the consensus estimate of $38.78 billion. Centene had a net margin of 2.03% and a return on equity of 13.85%. The firm’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.45 EPS. As a group, analysts expect that Centene Co. will post 6.86 earnings per share for the current fiscal year.
About Centene
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.
See Also
- Five stocks we like better than Centene
- 3 Best Fintech Stocks for a Portfolio Boost
- Energy Transfer: Powering Data With Dividends and Diversification
- The Most Important Warren Buffett Stock for Investors: His Own
- Qualcomm Stock Is Coiling for a Breakout
- Business Services Stocks Investing
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.